Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

Anne Wojcicki, co-founder and former CEO of 23andMe, is set to regain control of the DNA-testing company after a nonprofit ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, ...

Wojcicki, a co-founder and former CEO of 23andMe, is buying ‘substantially all’ of the company’s assets through a nonprofit.

Anne Wojcicki won a bid to purchase the genetic testing platform through her nonprofit TTAM Research Institute. The $305M deal was part of a bankruptcy auction, beating out offers from Regeneron ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy ...

June 13 (Reuters) - Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' (REGN.O), opens new tab offer for the ...